Ocrelizumab and its role in the treatment of multiple sclerosis: A systematic review of the literature
DOI:
https://doi.org/10.56294/sctconf2024924Keywords:
Multiple Sclerosis, Illness, Monoclonal Antibody, Drug, OcrelizumabAbstract
Introduction: multiple Sclerosis is an autoimmune, chronic, progressive disease of the central nervous system that affects the myelin sheaths, producing a dysfunction in the nerve impulse, it is one of the main causes of neurological disability in young adults. Unfortunately, there is no cure for this disease, but there are many treatments to mitigate the outbreaks and progression of the disease. One of the promising drugs is ocrelizumab, a humanized monoclonal antibody against the CD20 antigen of B cells that has recently been approved by the US (Food and Drug Administration) and European (European Medicines Agency) health agencies for the treatment of sclerosis. multiplex (MS) and is the first drug to be marketed for both relapsingremitting MS (RRMS) and primary progressive MS (PPMS).
Material and methods: a bibliographic search will be carried out in the different scientific databases, in order to investigate the role of ocrelizumab in the treatment of Multiple Sclerosis.
Conclusion: MS is a disease that so far has no cure; however, a wide range of treatments are available that must be chosen according to the patient and his need. Within the vast range of treatment arises monoclonal antibodies that are specialized glycoproteins that are part of the immune system, produced by B cells, with the ability to recognize specific molecules (antigens). They are among the most promising agents for the treatment of MS. The most Used is ocrelizumab
References
1. Cuevas-García CF, Segura-Méndez NH, Herrera-Sánchez DA. Current advances in multiple sclerosis immunopathology. Gac Med Mex. 2018;154(5):498–506.
2. Carretero Ares JL, Bowakim Dib W, Acebes Rey JM. Actualización: Esclerosis múltiple. MEDIFAM - Rev Med Fam y Comunitaria. 2001;11(9):516–29.
3. Jersild C, Hansen GS, Svejgaard A, Fog T, Thomsen M, Dupont B. Histocompatibility Determinants in Multiple Sclerosis, With Special Reference To Clinical Course. Lancet. 1973;302(7840):1221–5.
4. Cook SD, Rohowsky‐Kochan C, Bansil S, Dowling PC. Evidence for multiple sclerosis as an infectious disease. Acta Neurol Scand. 1995;91(161 S):34–42.
5. Koriem KMM. Corrigendum to ‘Multiple sclerosis: New insights and trends’ (Asian Pacific Journal of Tropical Biomedicine (2017) 7(5) (493–504) (S2221169116302453) (10.1016/j.apjtb.2016.03.009)). Asian Pac J Trop Biomed [Internet]. 2017;7(5):493–504. Available from: http://dx.doi.org/10.1016/j.apjtb.2017.02.001
6. Cases E, Sclerosis M. The History of MS. 1868;1–11.
7. Hegen H, Bsteh G, Berger T. ‘No evidence of disease activity’ – is it an appropriate surrogate in multiple sclerosis? Eur J Neurol. 2018;25(9):1107-e101.
8. CM P, DW P, Scheinberg L, WI M, FA D, GC E, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13(3):227–31.
9. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–73.
10. Andersson M, Alvarez-Cermeñio J, Bernardi G, Cogato I, Fredman P, Frederiksen J, et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: A consensus report. J Neurol Neurosurg Psychiatry. 1994;57(8):897–902.
11. Rovira A, Izquierdo G. Recomendaciones para la utilización e interpretación de los estudios de resonancia magnética en la esclerosis múltiple. 2010;25(4).
12. Bargiela NF, García CM, Arufe VG, Hermida JRV, Herranz IM. Fingolimod in multiple sclerosis: Profile of use in habitual practice. Eur J Hosp Pharm. 2020;27(6):346–9.
13. Mogica-Martínez MD. Uso terapéutico actual de la inmunoglobulina intravenosa. Rev Med Inst Mex Seguro Soc. 2006;44(2):81–6.
14. Castro P De. Plasmaféresis en la esclerosis múltiple. :57–62.
15. Sospedra M. Inmunoterapias en esclerosis múltiple. :71–80.
16. Juanatey A, Blanco-garcía L, Téllez N. Bt120423. 2018;66(12):423–33.
17. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 2006;54(8):2377–86.
Published
Issue
Section
License
Copyright (c) 2024 María Lucía Campos , Marcelo Adrian Estrin (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
